Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2195) 2195
Publication (203) 203
Book Review (25) 25
Book Chapter (11) 11
Magazine Article (8) 8
Newsletter (7) 7
Data Set (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1773) 1773
pyrazinamide - therapeutic use (1267) 1267
antitubercular agents - therapeutic use (1202) 1202
isoniazid - therapeutic use (978) 978
rifampin - therapeutic use (966) 966
female (928) 928
male (925) 925
tuberculosis (857) 857
pyrazinamide (842) 842
adult (805) 805
index medicus (728) 728
tuberculosis, pulmonary - drug therapy (692) 692
drug therapy, combination (607) 607
middle aged (560) 560
ethambutol - therapeutic use (532) 532
tuberculosis - drug therapy (477) 477
infectious diseases (389) 389
pharmacology & pharmacy (382) 382
mycobacterium tuberculosis - drug effects (368) 368
adolescent (362) 362
rifampin (359) 359
treatment outcome (320) 320
pyrazinamide - administration & dosage (319) 319
aged (316) 316
antitubercular agents - administration & dosage (311) 311
rifampin - administration & dosage (302) 302
microbiology (297) 297
animals (280) 280
isoniazid (276) 276
isoniazid - administration & dosage (272) 272
mycobacterium-tuberculosis (267) 267
streptomycin - therapeutic use (258) 258
antitubercular agents - adverse effects (241) 241
pulmonary tuberculosis (241) 241
respiratory system (239) 239
time factors (221) 221
child (216) 216
mycobacterium tuberculosis - isolation & purification (213) 213
rifampicin (200) 200
antitubercular agents - pharmacology (195) 195
drugs (193) 193
mycobacterium tuberculosis (186) 186
ethambutol (185) 185
drug therapy (180) 180
pyrazinamide - adverse effects (171) 171
tuberculosis, multidrug-resistant - drug therapy (164) 164
drug resistance (160) 160
tuberculosis, pulmonary - microbiology (159) 159
immunology (158) 158
pharmacokinetics (158) 158
pyrazinamide - pharmacology (157) 157
mice (154) 154
antibiotics, antitubercular - therapeutic use (153) 153
chemotherapy (152) 152
microbial sensitivity tests (150) 150
antitubercular agents (149) 149
drug administration schedule (149) 149
young adult (143) 143
drug resistance, microbial (141) 141
drug combinations (135) 135
ethambutol - administration & dosage (135) 135
medicine, general & internal (135) 135
antitubercular agents - pharmacokinetics (134) 134
rifampin - adverse effects (133) 133
sputum - microbiology (130) 130
ethionamide - therapeutic use (129) 129
follow-up studies (129) 129
child, preschool (125) 125
retrospective studies (124) 124
isoniazid - adverse effects (122) 122
risk factors (116) 116
analysis (115) 115
antituberculosis drugs (110) 110
infection (109) 109
recurrence (107) 107
moxifloxacin (106) 106
mycobacterium tuberculosis - genetics (106) 106
infant (104) 104
health aspects (102) 102
prospective studies (101) 101
tuberculosis, pulmonary - complications (100) 100
tuberculosis, pulmonary - diagnosis (100) 100
cycloserine - therapeutic use (99) 99
research (98) 98
medicine (97) 97
research article (97) 97
rifampin - pharmacokinetics (96) 96
hiv (95) 95
tuberculosis - microbiology (95) 95
therapy (94) 94
care and treatment (92) 92
hepatotoxicity (92) 92
pyrazinamide - pharmacokinetics (91) 91
aged, 80 and over (87) 87
children (84) 84
isoniazid - pharmacology (84) 84
susceptibility (83) 83
hiv infections - complications (82) 82
diagnosis (81) 81
chemical and drug induced liver injury - etiology (78) 78
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1898) 1898
French (83) 83
Spanish (64) 64
German (55) 55
Russian (45) 45
Japanese (20) 20
Italian (17) 17
Polish (13) 13
Chinese (11) 11
Portuguese (9) 9
Turkish (6) 6
Dutch (4) 4
Hebrew (2) 2
Hungarian (2) 2
Romanian (2) 2
Swedish (2) 2
Danish (1) 1
Korean (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Randomized Pilot Trial of Eight Weeks of Bedaquiline (TMC207) Treatment for Multidrug-Resistant Tuberculosis: Long-Term Outcome, Tolerability, and Effect on Emergence of Drug Resistance
by A. H. Diacon and P. R. Donald and A. Pym and M. Grobusch and R. F. Patientia and R. Mahanyele and N. Bantubani and R. Narasimooloo and T. De Marez and R. van Heeswijk and N. Lounis and P. Meyvisch and K. Andries and D. F. McNeeley
Antimicrobial Agents and Chemotherapy, ISSN 0066-4804, 06/2012, Volume 56, Issue 6, pp. 3271 - 3276
Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit... 
MYCOBACTERIUM-TUBERCULOSIS | AFRICA | DIARYLQUINOLINE TMC207 | PHOSPHOLIPIDOSIS | SUSCEPTIBILITY | PYRAZINAMIDE | MICROBIOLOGY | PHARMACOLOGY & PHARMACY | Humans | Ofloxacin - therapeutic use | Male | Clarithromycin - therapeutic use | Dapsone - therapeutic use | Erythromycin - therapeutic use | Cycloserine - therapeutic use | Oxazolidinones - therapeutic use | Diarylquinolines | Female | Quinolines - therapeutic use | Isoxazoles - therapeutic use | Antitubercular Agents - therapeutic use | Tuberculosis, Multidrug-Resistant - drug therapy | Chest | Acne | Lung | Clinical trials | Ethionamide | Nausea | Drug resistance | Ofloxacin | Hearing | Pain | Tuberculosis | Sputum | ethambutol | Pharmacokinetics | Clinical Therapeutics
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis
by Caminero, José A, Dr and Sotgiu, Giovanni, PhD and Zumla, Alimuddin, FRCP and Migliori, Giovanni Battista, MD
Lancet Infectious Diseases, The, ISSN 1473-3099, 2010, Volume 10, Issue 9, pp. 621 - 629
Summary Multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis are generally thought to have high mortality rates. However, many cases can... 
Infectious Disease | MYCOBACTERIUM-TUBERCULOSIS | INVITRO ACTIVITY | TUBERCLE-BACILLI | INFECTIOUS DISEASES | EARLY BACTERICIDAL ACTIVITY | TREATMENT OUTCOMES | CROSS-RESISTANCE | MDR-TB | XDR-TB | CLAVULANIC ACID | RPOB MUTATIONS | Extensively Drug-Resistant Tuberculosis - drug therapy | Levofloxacin | Drug Resistance, Multiple | Humans | Ofloxacin - therapeutic use | Fluoroquinolones - therapeutic use | Kanamycin - therapeutic use | Pyrazinamide - therapeutic use | Capreomycin - therapeutic use | Amikacin - therapeutic use | Antitubercular Agents - classification | Tuberculosis - drug therapy | Antitubercular Agents - standards | Isoniazid - therapeutic use | Ethambutol - therapeutic use | Antitubercular Agents - therapeutic use | Drugs | Drug resistance in microorganisms | Care and treatment | Tuberculosis | Amoxicillin | Antitubercular agents
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial
by Boeree, Martin J, PhD and Heinrich, Norbert, MD and Aarnoutse, Rob, PhD and Diacon, Andreas H, PhD and Dawson, Rodney, PhD and Rehal, Sunita, MSc and Kibiki, Gibson S, Prof and Churchyard, Gavin, Prof and Sanne, Ian, FRCP and Ntinginya, Nyanda E, MD and Minja, Lilian T, MD and Hunt, Robert D, BSc and Charalambous, Salome, PhD and Hanekom, Madeleine, PhD and Semvua, Hadija H, PhD and Mpagama, Stellah G, PhD and Manyama, Christina, MD and Mtafya, Bariki, MSc and Reither, Klaus, MD and Wallis, Robert S, Prof and Venter, Amour, NatDipMicr and Narunsky, Kim, MD and Mekota, Anka, PhD and Henne, Sonja, MSc and Colbers, Angela, PhD and van Balen, Georgette Plemper, PhD and Gillespie, Stephen H, Prof and Phillips, Patrick P J, PhD and Hoelscher, Michael, Prof and PanACEA Consortium and PanACEA consortium
Lancet Infectious Diseases, The, ISSN 1473-3099, 2017, Volume 17, Issue 1, pp. 39 - 49
Summary Background Tuberculosis is the world's leading infectious disease killer. We aimed to identify shorter, safer drug regimens for the treatment of... 
Infectious Disease | MYCOBACTERIUM-TUBERCULOSIS | DRUG | INFECTIOUS DISEASES | SOLID CULTURE | PHARMACOKINETICS | SPUTUM | PULMONARY TUBERCULOSIS | PHASE-II | RANGING TRIAL | COMBINATION | ANTITUBERCULOSIS TREATMENT | Drug Administration Schedule | Humans | Tanzania | Fluoroquinolones - therapeutic use | Male | Tuberculosis, Pulmonary - drug therapy | Ethylenediamines - therapeutic use | Pyrazinamide - therapeutic use | Tuberculosis, Pulmonary - diagnosis | Adamantane - therapeutic use | Adult | Female | Isoniazid - therapeutic use | Rifampin - therapeutic use | South Africa | Drug Therapy, Combination | Ethambutol - therapeutic use | Adamantane - analogs & derivatives | Antitubercular Agents - therapeutic use | Medical colleges | Tuberculosis | Pharmacy | Communicable diseases | Lung diseases | Clinical trials | Drugstores | Dosage and administration | Research institutes | Rifampin | Public health | Moxifloxacin | Analysis | Studies | Consortia | Drug dosages
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis
by Dawson, Rodney, MD and Diacon, Andreas H, MD and Everitt, Daniel, Dr and van Niekerk, Christo, MD and Donald, Peter R, MD and Burger, Divan A, MCom and Schall, Robert, PhD and Spigelman, Melvin, MD and Conradie, Almari, MPh and Eisenach, Kathleen, PhD and Venter, Amour, NatDipMicr and Ive, Prudence, FCP[SA] and Page-Shipp, Liesl, MBBCh and Variava, Ebrahim, MD and Reither, Klaus, MD and Ntinginya, Nyanda E, MD and Pym, Alexander, MD and von Groote-Bidlingmaier, Florian, MD and Mendel, Carl M, MD
Lancet, The, ISSN 0140-6736, 2015, Volume 385, Issue 9979, pp. 1738 - 1747
Summary Background New antituberculosis regimens are urgently needed to shorten tuberculosis treatment. Following on from favourable assessment in a 2 week... 
Internal Medicine | MYCOBACTERIUM-TUBERCULOSIS | ETHAMBUTOL | MEDICINE, GENERAL & INTERNAL | PHARMACOKINETICS | EARLY BACTERICIDAL ACTIVITY | Sputum - microbiology | Humans | Tanzania | Fluoroquinolones - therapeutic use | Male | Treatment Outcome | Tuberculosis, Pulmonary - drug therapy | Colony Count, Microbial | Moxifloxacin | Pyrazinamide - therapeutic use | Young Adult | Nitroimidazoles - therapeutic use | Adolescent | Adult | Female | Isoniazid - therapeutic use | Rifampin - therapeutic use | South Africa | Drug Therapy, Combination | Ethambutol - therapeutic use | Antitubercular Agents - therapeutic use | Tuberculosis, Multidrug-Resistant - drug therapy | Clinical trials | Tuberculosis | International cooperation | Drug therapy | Pyrazinamide | Analysis | Pulmonary tuberculosis | Drug resistance | Efficiency
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Four-Month Moxifloxacin-Based Regimens for Drug-Sensitive Tuberculosis
by Gillespie, Stephen H and Crook, Angela M and McHugh, Timothy D and Mendel, Carl M and Meredith, Sarah K and Murray, Stephen R and Pappas, Frances and Phillips, Patrick P.J and Nunn, Andrew J and REMoxTB Consortium
The New England Journal of Medicine, ISSN 0028-4793, 10/2014, Volume 371, Issue 17, pp. 1577 - 1587
One approach to improving tuberculosis therapy is to shorten the duration from 6 months to 4 months. In this trial in over 1900 patients with smear-positive... 
GATIFLOXACIN | ETHAMBUTOL | RELAPSE | MEDICINE, GENERAL & INTERNAL | RESISTANT TUBERCULOSIS | BACTERICIDAL ACTIVITY | MURINE TUBERCULOSIS | PHARMACOKINETICS | PULMONARY TUBERCULOSIS | RANDOMIZED-TRIAL | PHASE-II | Antitubercular Agents - adverse effects | Double-Blind Method | Drug Administration Schedule | HIV Seropositivity - complications | Humans | Kaplan-Meier Estimate | Fluoroquinolones - therapeutic use | Male | Tuberculosis, Pulmonary - drug therapy | Fluoroquinolones - adverse effects | Mycobacterium tuberculosis - isolation & purification | Pyrazinamide - therapeutic use | Tuberculosis, Pulmonary - complications | Young Adult | Adult | Female | Isoniazid - therapeutic use | Rifampin - therapeutic use | Drug Therapy, Combination | Ethambutol - therapeutic use | Antitubercular Agents - therapeutic use | Dose-response relationship (Biochemistry) | Treatment outcome | Care and treatment | Tuberculosis | Analysis | Dosage and administration | Moxifloxacin | Studies | Motivation | Ethambutol | Drug development | Pyrazinamide | Drug therapy | Isoniazid | Rifampin | Patients
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text A Four-Month Gatifloxacin-Containing Regimen for Treating Tuberculosis
by Merle, Corinne S and Fielding, Katherine and Sow, Omou Bah and Gninafon, Martin and Lo, Mame B and Mthiyane, Thuli and Odhiambo, Joseph and Amukoye, Evans and Bah, Boubacar and Kassa, Ferdinand and N'Diaye, Alimatou and Rustomjee, Roxana and de Jong, Bouke C and Horton, John and Perronne, Christian and Sismanidis, Charalambos and Lapujade, Olivier and Olliaro, Piero L and Lienhardt, Christian and OFLOTUB Gatifloxacin TB Project and OFLOTUB/Gatifloxacin for Tuberculosis Project
The New England Journal of Medicine, ISSN 0028-4793, 10/2014, Volume 371, Issue 17, pp. 1588 - 1598
Shortening treatment regimens for tuberculosis may help control the disease. In this trial, patients with tuberculosis in sub-Saharan Africa received either a... 
TRIAL | PULMONARY TUBERCULOSIS | ETHAMBUTOL | MEDICINE, GENERAL & INTERNAL | PHASE-II | MOXIFLOXACIN | Antitubercular Agents - adverse effects | Blood Glucose - analysis | Drug Administration Schedule | Humans | Fluoroquinolones - therapeutic use | Male | Tuberculosis, Pulmonary - drug therapy | Fluoroquinolones - adverse effects | Mycobacterium tuberculosis - isolation & purification | Pyrazinamide - therapeutic use | Intention to Treat Analysis | Adult | Female | Isoniazid - therapeutic use | Rifampin - therapeutic use | Drug Therapy, Combination | Ethambutol - therapeutic use | Antitubercular Agents - therapeutic use | Dose-response relationship (Biochemistry) | Treatment outcome | Care and treatment | Tuberculosis | Analysis | Motivation | Gatifloxacin | Ethambutol | Disease management | Drug therapy | Isoniazid | Disease control | Rifampin | Patients
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. High effectiveness of a 12-month regimen for MDR-TB patients in Cameroon
by Kuaban, C and Noeske, J and Rieder, H.L and Aït-Khaled, N and Abena Foe, J.L and Trébucq, A
International Journal of Tuberculosis and Lung Disease, ISSN 1027-3719, 05/2015, Volume 19, Issue 5, pp. 517 - 524
SETTING: Two specialised multidrug-resistant tuberculosis (MDR-TB) treatment units in Cameroon. OBJECTIVE: To assess outcome and adverse drug events with a... 
Cameroon | Short-course | Treatment | Tuberculosis | Multidrug resistance | multidrug resistance | treatment | DEFINITIONS | INFECTIOUS DISEASES | RESPIRATORY SYSTEM | tuberculosis | short-course | MULTIDRUG-RESISTANT TUBERCULOSIS | Medication Adherence - statistics & numerical data | Antitubercular Agents - adverse effects | Confidence Intervals | Prospective Studies | Humans | Middle Aged | Male | Tuberculosis, Multidrug-Resistant - diagnosis | Dose-Response Relationship, Drug | Young Adult | Time Factors | Adult | Female | Isoniazid - therapeutic use | Drug Therapy, Combination | Ethambutol - therapeutic use | Odds Ratio | Antitubercular Agents - therapeutic use | Clofazimine - therapeutic use | Drug Administration Schedule | Risk Assessment | Fluoroquinolones - therapeutic use | Treatment Outcome | Kanamycin - therapeutic use | Prothionamide - therapeutic use | Pyrazinamide - therapeutic use | Drug-Related Side Effects and Adverse Reactions - epidemiology | Adolescent | Aged | Developing Countries | Cohort Studies | Tuberculosis, Multidrug-Resistant - drug therapy
Journal Article
Details down arrow
8. A phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis
by Rustomjee, R and Lienhardt, C and Kanyok, T and Davies, G.R and Levin, J and Mthiyane, T and Reddy, C and Sturm, A.W and Sirgel, F.A and Allen, J and Coleman, D.J and Fourie, B and Mitchison, D.A and Bah-Sow, O.Y and Diop, H and Fielding, K and Gninafon, M and Mitchison, D and Lienhardt, C and Odhiambo, J and Perronne, C and Portaels, F and Rustomjee, R and Ramjee, A and Master, I and Olowolagba, A and Chinappa, T and Osburne, G and Bamber, S and Pala, A.S and Pillay, L and Tembe, C and Mpangase, P and Hadebe, T and Ngcobo, C.P and Mkhize, Z and Dlamini, C.N and Gill, L and Dube, T and Saul, M and Merle, C and Suma, K.F and Gatifloxacin TB OFLOTUB Study Team and Gatifloxacin for TB (OFLOTUB) study team
International Journal of Tuberculosis and Lung Disease, ISSN 1027-3719, 02/2008, Volume 12, Issue 2, pp. 128 - 138
SETTING: Current treatment for pulmonary tuberculosis (TB) might be shortened by the incorporation of fluoroquinolones (FQs). OBJECTIVES: A Phase H study aimed... 
FQs | Modelling | Randomised clinical trial | Pulmonary tuberculosis | MYCOBACTERIUM-TUBERCULOSIS | ANTITUBERCULOSIS DRUGS | INFECTIOUS DISEASES | EARLY PHARMACODYNAMIC MEASURES | REGIMEN | SHORT-COURSE CHEMOTHERAPY | RIFAMPICIN | modelling | pulmonary tuberculosis | CONTROLLED CLINICAL-TRIAL | IN-VITRO | RESPIRATORY SYSTEM | FLUOROQUINOLONES | randomised clinical trial | Sputum - microbiology | Aza Compounds - therapeutic use | Humans | Middle Aged | Ofloxacin - therapeutic use | Fluoroquinolones - therapeutic use | Male | Colony Count, Microbial | Pyrazinamide - therapeutic use | Anti-Bacterial Agents - therapeutic use | Adolescent | Adult | Female | Isoniazid - therapeutic use | Rifampin - therapeutic use | Aged | Quinolines - therapeutic use | Drug Therapy, Combination | Nonlinear Dynamics | Antitubercular Agents - therapeutic use
Journal Article
Details down arrow
9. Successful '9-month Bangladesh regimen' for multidrug-resistant tuberculosis among over 500 consecutive patients
by Aung, KJM and Van Deun, A and Declercq, E and Sarker, MR and Das, PK and Hossain, MA and Rieder, HL
INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, ISSN 1027-3719, 10/2014, Volume 18, Issue 10, pp. 1180 - 1187
SETTING: Tuberculosis (TB) program, Damien Foundation Projects, Bangladesh. OBJECTIVE: To summarize the outcome and its determinants of the first treatment for... 
MYCOBACTERIUM-TUBERCULOSIS | multidrug resistance | treatment | GATIFLOXACIN | DIAGNOSIS | INFECTIOUS DISEASES | RESPIRATORY SYSTEM | tuberculosis | ADULTS | standardization | Sputum - microbiology | Multivariate Analysis | Prospective Studies | Follow-Up Studies | Humans | Middle Aged | Male | Mycobacterium tuberculosis - drug effects | Dose-Response Relationship, Drug | Young Adult | Anti-Bacterial Agents - therapeutic use | Drug Resistance, Multiple, Bacterial | Adult | Female | Child | Clofazimine - therapeutic use | Risk Factors | Fluoroquinolones - therapeutic use | Logistic Models | Treatment Outcome | Kanamycin - therapeutic use | Pyrazinamide - therapeutic use | Bangladesh | Adolescent | Aged | Tuberculosis, Multidrug-Resistant - drug therapy
Journal Article
Details down arrow
10. Full Text Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial
by Conde, Marcus B, MD and Efron, Anne, MSN and Loredo, Carla, RN and De Souza, Gilvan R Muzy, MD and Graça, Nadja P, MD and Cezar, Michelle C, MD and Ram, Malathi, PhD and Chaudhary, Mohammad A, PhD and Bishai, William R, Prof and Kritski, Afranio L, MD and Chaisson, Richard E, Prof
Lancet, The, ISSN 0140-6736, 2009, Volume 373, Issue 9670, pp. 1183 - 1189
Summary Background New treatments are needed to shorten the time required to cure tuberculosis and to treat drug-resistant strains. The fluoroquinolone... 
Internal Medicine | PULMONARY TUBERCULOSIS | GATIFLOXACIN | MEDICINE, GENERAL & INTERNAL | REGIMENS | CULTURE | EARLY BACTERICIDAL ACTIVITY | Fluoroquinolones | Sputum - microbiology | Multivariate Analysis | Tuberculosis, Pulmonary - microbiology | Antitubercular Agents - adverse effects | Aza Compounds - therapeutic use | Humans | Aza Compounds - adverse effects | Male | Tuberculosis, Pulmonary - drug therapy | Ethambutol - adverse effects | Time Factors | Adult | Female | Isoniazid - therapeutic use | Rifampin - therapeutic use | Drug Therapy, Combination | Ethambutol - therapeutic use | Brazil - epidemiology | Antitubercular Agents - therapeutic use | Double-Blind Method | Drug Administration Schedule | Kaplan-Meier Estimate | Logistic Models | Treatment Outcome | Pyrazinamide - therapeutic use | Tuberculosis, Pulmonary - mortality | Tuberculosis, Pulmonary - diagnosis | Quinolines - therapeutic use | Quinolines - adverse effects | Complications and side effects | Tuberculosis | Ethambutol | Dosage and administration | Moxifloxacin | Research | Drug therapy | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text High-Dose Rifapentine with Moxifloxacin for Pulmonary Tuberculosis
by Jindani, Amina and Harrison, Thomas S and Nunn, Andrew J and Phillips, Patrick P.J and Churchyard, Gavin J and Charalambous, Salome and Hatherill, Mark and Geldenhuys, Hennie and McIlleron, Helen M and Zvada, Simbarashe P and Mungofa, Stanley and Shah, Nasir A and Zizhou, Simukai and Magweta, Lloyd and Shepherd, James and Nyirenda, Sambayawo and van Dijk, Janneke H and Clouting, Heather E and Coleman, David and Bateson, Anna L.E and McHugh, Timothy D and Butcher, Philip D and Mitchison, Denny A and RIFAQUIN Trial Team
The New England Journal of Medicine, ISSN 0028-4793, 10/2014, Volume 371, Issue 17, pp. 1599 - 1608
In this report from sub-Saharan Africa, a 4-month regimen of moxifloxacin and rifapentine for pulmonary tuberculosis was not as beneficial as two 6-month... 
CONTROLLED-TRIAL | MEDICINE, GENERAL & INTERNAL | PHASE | MULTICENTER | MULTIPLICITY | HIV | POPULATION PHARMACOKINETICS | REGIMENS | CHEMOTHERAPY | ONCE-WEEKLY RIFAPENTINE | RECORDING-SYSTEM | Rifampin - analogs & derivatives | Antitubercular Agents - adverse effects | Coinfection | HIV Seropositivity - complications | Humans | Middle Aged | Male | Tuberculosis, Pulmonary - drug therapy | Tuberculosis, Pulmonary - complications | Young Adult | Rifampin - adverse effects | Adult | Female | Isoniazid - therapeutic use | Rifampin - therapeutic use | Rifampin - administration & dosage | Drug Therapy, Combination | Ethambutol - therapeutic use | Antitubercular Agents - therapeutic use | Fluoroquinolones - administration & dosage | Drug Administration Schedule | Kaplan-Meier Estimate | Fluoroquinolones - adverse effects | Mycobacterium tuberculosis - isolation & purification | Pyrazinamide - therapeutic use | Adolescent | Dose-response relationship (Biochemistry) | Treatment outcome | Care and treatment | Analysis | Pulmonary tuberculosis | Dosage and administration | Moxifloxacin | Rifapentine | Tuberculosis | Motivation | Sputum | Clinical trials | Ethambutol | Pyrazinamide | Drug therapy | Isoniazid | Rifampin | Patients | Developing countries--LDCs
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights